This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Fetal striatal grafting slows motor and cognitive decline of Huntington’s disease


Paganini, M., Biggeri, A., Romoli, A. M., Mechi, C., Ghelli, E., Berti, V., Pradella, S., Bucciantini, S., Catelan, D., Saccardi, R., Lombardini, L., Mascalchi, M., Massacesi, L., Porfirio, B., Di Lorenzo, N., Vannelli, G. B., Gallina, P.


Journal Of Neurology, Neurosurgery, And Psychiatry, Volume: 85, No.: 9, Pages.: 974-981

Year of Publication



Objective: To assess the clinical effect of caudate-putaminal transplantation of fetal striatal tissue in Huntington’s disease (HD).; Methods: We carried out a follow-up study on 10 HD transplanted patients and 16 HD not-transplanted patients. All patients were evaluated with the Unified HD Rating Scale (UHDRS) whose change in motor, cognitive, behavioural and functional capacity total scores were considered as outcome measures. Grafted patients also received morphological and molecular neuroimaging.; Results: Patients were followed-up from disease onset for a total of 309.3 person-years (minimum 5.3, median 11.2 years, maximum 21.6 years). UHDRS scores have been available since 2004 (median time of 5.7 years since onset, minimum zero, maximum 17.2 years). Median post-transplantation follow-up was 4.3 years, minimum 2.8, maximum 5.1 years. Adjusted post-transplantation motor score deterioration rate was reduced compared to the pretransplantation period, and to that of not-transplanted patients by 0.9 unit/years (95% CI 0.2 to 1.6). Cognitive score deterioration was reduced of 2.7 unit/years (95% CI 0.1 to 5.3). For grafted patients the 2-year post-transplantation [(18)F]fluorodeoxyglucose positron emission tomography (PET) showed striatal/cortical metabolic increase compared to the presurgical evaluation; 4-year post-transplantation PET values were slightly decreased, but remained higher than preoperatively. [(123)I]iodobenzamide single photon emission CT demonstrated an increase in striatal D2-receptor density during postgrafting follow-up.; Conclusions: Grafted patients experienced a milder clinical course with less pronounced motor/cognitive decline and associated brain metabolism improvement. Life-time follow-up may ultimately clarify whether transplantation permanently modifies the natural course of the disease, allowing longer sojourn time at less severe clinical stage, and improvement of overall survival.; Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to

Bibtex Citation

@article{Paganini_2013, doi = {10.1136/jnnp-2013-306533}, url = {}, year = 2013, month = {dec}, publisher = {{BMJ}}, volume = {85}, number = {9}, pages = {974--981}, author = {M. Paganini and A. Biggeri and A. M. Romoli and C. Mechi and E. Ghelli and V. Berti and S. Pradella and S. Bucciantini and D. Catelan and R. Saccardi and L. Lombardini and M. Mascalchi and L. Massacesi and B. Porfirio and N. Di Lorenzo and G. B. Vannelli and P. Gallina}, title = {Fetal striatal grafting slows motor and cognitive decline of Huntington{textquotesingle}s disease}, journal = {Journal of Neurology, Neurosurgery {&} Psychiatry} }


adult, brain tissue transplantation, caudateputaminal, cerebral cortex, corpus striatum, diagnostic use, female, fetal, fetal tissue transplantation, fluorodeoxyglucose f18, functional neuroimaging, humans, huntington disease, huntingtons, iodobenzenes, male, metabolism, middle aged, neuropsychological tests, of, physiopathology, psychology, receptors dopamine d2, stereotaxic surgery, striatal, surgery, therapy, tissue, transplantation, treatment outcome

Countries of Study


Types of Dementia


Types of Study

Non randomised controlled trial

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Non-pharmacological Treatment

Non-Pharmaceutical Interventions